BPC-157 for dogs: FDA status and what the dog studies found
Veterinary review status: Not yet completed. A page will name the reviewer, credential, scope, and date if and when a licensed veterinarian reviews it. Until then, no veterinary-review label is used.
TREATMENT RECORD · DOGS · EMERGING AND UNAPPROVED CLAIM
If your dog has already received BPC-157 and something has changed—or has collapsed, has trouble breathing, has pale, white, or blue gums, cannot stand, is bleeding uncontrollably, is having a seizure, has a swollen painful belly, keeps retching without bringing anything up, suffered major trauma, or is worsening quickly—contact a veterinarian or emergency animal hospital now. This page cannot tell you it is safe to wait.
The Pet Treatment Index Editorial Desk · Independent pet-treatment research
Published: August 29, 2026 · Last reviewed: August 29, 2026 · Last verified: August 29, 2026
Source versions: FDA BPC-157 briefing memorandum dated May 11, 2026; 21 CFR 216.23 current through August 27, 2026; FDA animal-compounding pages checked August 29, 2026.
Veterinary review status: Not yet completed. A page will name the reviewer, credential, scope, and date if and when a licensed veterinarian reviews it. Until then, no veterinary-review label is used.
No FDA-approved, conditionally approved, or indexed BPC-157 product for dogs was located in US animal-drug records checked August 29, 2026. FDA’s May 2026 human-drug review also reported that its search found no approved BPC-157 product in any country at that time. Two published papers include healthy Beagle dogs. One studied how the peptide moved through the body; the other studied acute and 28-day toxicity. Neither tested whether a ligament, joint, wound, gut problem, or surgical patient healed. No controlled canine efficacy trial was located. Start with a diagnosis.
Educational information for pet owners—not veterinary advice, a diagnosis, or a treatment recommendation. A veterinarian’s examination and diagnosis set treatment. This page does not calculate doses, name sellers, or tell you to start, stop, switch, combine, or substitute anything.
Get help now if any of this is happening
Contact your veterinarian or the nearest emergency animal hospital immediately if your dog has:
- collapsed, or is suddenly unable to stand or use one or more legs
- trouble breathing, or pale, white, or blue gums
- a swollen, hard, or painful belly
- repeated retching or vomiting without bringing anything up
- blood in vomit or stool, or black tarry stool
- bleeding that will not stop, or a seizure
- suffered major trauma, or is getting worse quickly
This page cannot examine your dog or decide whether waiting is safe.
If you have already given your dog a peptide and something has changed: call your veterinarian now and tell them exactly what the product label says, how much was given, by what route, and when. Bring the vial, package, and label. If you cannot reach your veterinarian, the ASPCA Animal Poison Control Center is available 24/7 at (888) 426-4435; a consultation fee may apply.
This applies to you if
- You are in the United States, researching BPC-157 for a dog.
- Your dog has a limp, a torn or partly torn ligament, arthritis, a gut problem, a wound, or is recovering from surgery.
- You found BPC-157 online, or a clinic, friend, video, or AI answer brought it up, and you are deciding whether to pursue it.
This is not your situation if
- Your dog may be having an emergency. Use the block above.
- You want a dose, a mixing or injection guide, or a place to buy it. This page gives none of those.
- You are asking about a cat or a person.
- You want this page to tell you why your dog is limping. It cannot. A hands-on examination can.
Start with where you actually are
| Your situation | What this page can answer | What needs a veterinarian | Go to |
|---|---|---|---|
| Emergency signs above | Nothing that should delay care | Everything | Emergency care now |
| I already gave my dog a peptide | What FDA and the published dog studies do and do not show | Whether your dog is affected and what monitoring is needed | Safety findings |
| Limping, no diagnosis yet | Why the peptide question comes second | The cause and urgency of the limp | In-person examination |
| Diagnosed CCL or knee injury | Whether canine evidence supports BPC-157 | Surgery, rehabilitation, or conservative-care decisions for this dog | Access and established alternatives |
| Diagnosed osteoarthritis | Whether BPC-157 has clinical dog evidence | Which established option fits this dog | Dog Treatment Records |
| My veterinarian raised BPC-157 | What to ask about status, identity, evidence, monitoring, and alternatives | Whether any proposal is appropriate and lawful in the specific case | Vet Conversation Sheet |
| Reading ahead, no current condition | The full status and evidence picture | Nothing yet | Read on |
The short answers
| Question | Answer | What it rests on | What would change it |
|---|---|---|---|
| Is BPC-157 approved for dogs? | No approved, conditionally approved, or indexed canine product was located in US records. FDA’s May 2026 review also reported no approved BPC-157 product in any country at the time of its search. | Animal Drugs @ FDA, Green Book, FDA Index, FDA BPC-157 briefing | A new approval, conditional approval, or other lawful veterinary marketing status |
| Is it on FDA’s animal office-stock list? | No. It is absent from the current list. That list governs one office-stock enforcement-discretion pathway; it is not the complete rule for every patient-specific prescription. | FDA CVM office-stock list and GFI #256 Q&A | FDA adds it to the list or changes the policy |
| Are there studies in dogs? | Yes—two published papers involving healthy Beagles. One is pharmacokinetics; the other contains acute and repeat-dose toxicity work. | He et al. 2022; Xu et al. 2020; FDA review | A canine clinical study in dogs that actually have the condition |
| Does it work? | Benefit is not established for any condition in dogs. | No controlled canine efficacy trial located | A relevant, adequately controlled canine trial |
| Is it safe for dogs? | Safety is not established. FDA identified altered clotting and other laboratory changes in the 28-day dog study, while longer-term and route-specific data remain missing. | FDA’s reanalysis of Xu et al. 2020 | Larger, longer studies in relevant canine patients and formulations |
Dog studies exist. That is the part most summaries miss. What those studies actually measured matters more.
1. What BPC-157 is, and what this record covers
BPC-157 is a synthetic peptide reported to contain 15 amino acids. This record covers claims about using it in dogs. It does not cover cats, people, dosing, mixing, injecting, or where to buy anything.
One detail matters more than it sounds. FDA treats BPC-157 free base and BPC-157 acetate as different bulk drug substances. In its May 2026 review, FDA said “BPC-157” is a common name rather than a standardized USAN and reported finding multiple salts and derivatives—including different active molecules—sold under that same common name. FDA treated that inconsistency as a safety risk because the name alone may not identify the intended substance.
So “BPC-157” on a label does not by itself settle exactly which active substance is present. Hold onto that. It comes back in the safety section.
Owners usually arrive here about one of five things: a torn cruciate ligament, arthritis, a gut problem, a wound, or recovery after surgery. Every one of those is a claim under review, not an established canine use.
2. Is BPC-157 FDA approved for dogs?
No FDA-approved, conditionally approved, or indexed BPC-157 product for dogs was located. The animal-drug records below were checked on August 29, 2026. Separately, FDA’s May 2026 human-drug compounding review reported that its global search found no approved product containing BPC-157 in any country at that time.
The site’s regulatory label for this record is No established veterinary marketing status located. That is a dated finding about the records checked—not a legal opinion about every fact pattern or jurisdiction.
The records checked
| Record | What it lists | Result | What the result means | What it does not mean |
|---|---|---|---|---|
| Animal Drugs @ FDA | Approved and conditionally approved animal drugs | No BPC-157 entry located | No approved or conditionally approved canine product found | Not a legal opinion about every possible use |
| FDA Green Book | Most approved and conditionally approved animal-drug products | No BPC-157 entry located | No listed approved animal-drug product found | Does not cover indexed drugs |
| FDA Index for minor species | Legally marketed unapproved new animal drugs for eligible minor species | No BPC-157 entry located | No indexed entry found | Dogs are a major species, not a minor species |
| CVM animal office-stock list | Bulk substances within FDA’s office-stock enforcement-discretion policy for stated species and uses | BPC-157 not listed | That office-stock pathway does not cover BPC-157 | The list is not the complete rule for patient-specific veterinary compounding |
Why the July 2026 headlines do not approve anything for your dog
In July 2026, FDA’s human-drug Pharmacy Compounding Advisory Committee discussed BPC-157 free base and acetate for possible inclusion on the human 503A Bulks List. FDA’s meeting page identifies the use reviewed as ulcerative colitis in people. Advisory-committee recommendations are nonbinding, and FDA retains the regulatory decision.
When checked, BPC-157 was not in 21 CFR 216.23, the current 503A Bulks List. FDA staff’s May 2026 briefing recommendation was not to add BPC-157 free base or acetate, citing characterization, safety, effectiveness, and historical-use concerns.
None of that is an animal-drug approval. It also does not place BPC-157 on FDA Center for Veterinary Medicine’s animal office-stock list.
| Question | Human compounding track | Animal track for a dog |
|---|---|---|
| Which FDA center is involved? | Center for Drug Evaluation and Research | Center for Veterinary Medicine |
| Which framework is relevant? | Section 503A and 21 CFR 216.23 | Animal-drug law plus GFI #256 enforcement-discretion policies |
| Is this an approval pathway? | No. Compounding-list status is not drug approval. | No. Compounding under enforcement discretion does not approve the preparation. |
| What did FDA review in July 2026? | Possible 503A-list inclusion; FDA evaluated ulcerative colitis | No corresponding canine approval review was identified |
| Is BPC-157 on the current list checked? | No, not in 21 CFR 216.23 | No, not on the animal office-stock list |
| Does the animal office-stock list decide every prescription? | Not applicable | No. Patient-specific prescriptions are a separate, fact-dependent pathway under GFI #256. |
| Does either track establish benefit in dogs? | No | No |
Three things are easy to blur: an advisory discussion, placement on a compounding list, and approval of a drug. They are not the same event.
The tendon claim regulators could not evaluate
BPC-157 was nominated on the human side for ulcerative colitis, Crohn’s disease, celiac disease, and tendonitis. FDA evaluated ulcerative colitis for the 2026 proceeding. It did not evaluate tendonitis because the nomination lacked enough information, and FDA reported that it did not identify clinical studies in that population.
The tendon and ligament claim is the reason many dog owners are here. A human compounding nomination did not establish it, and no canine clinical efficacy trial was located.
Both nominations cited in FDA’s briefing had been withdrawn. FDA continued the evaluation on its own initiative.
3. What dog evidence actually exists
Two published papers report BPC-157 administration to healthy Beagle dogs. One measured pharmacokinetics—how quickly the tested substance appeared and disappeared in blood. The other reported acute and 28-day repeat-dose toxicity work. Neither paper tested a dog with a torn ligament, arthritis, a wound, gastrointestinal disease, or a surgical recovery problem.
No controlled canine efficacy trial was located as of August 29, 2026.
| Source | Species, population, and denominator | Design, route, duration, comparator | What it measured and found | Funding/conflicts | What it can establish | What it cannot establish |
|---|---|---|---|---|---|---|
| He et al., 2022 | Six healthy Beagles—three male and three female; 10–12 months old; 9.8–12.8 kg; laboratory study in China | Single intravenous and intramuscular administrations plus seven days of repeat intramuscular administration; no disease comparator | Plasma pharmacokinetics. The reported half-life after intravenous administration was 5.27 minutes; the dog work did not test healing. The paper’s excretion, metabolism, and tissue-distribution experiments were in rats, not dogs. | Chinese public research grants; authors declared no commercial or financial relationships that could be construed as a conflict | How the tested material behaved in the blood of six healthy laboratory dogs after IV/IM administration | Pain relief, ligament repair, arthritis benefit, wound healing, oral or under-the-skin behavior, or clinical safety in sick dogs |
| Xu et al., 2020—acute component | Healthy Beagles; dog denominator not stated in the accessible abstract or FDA summary | Single intramuscular administration; 14-day observation; laboratory toxicology | Authors reported no overt acute toxicity or organ-tissue findings under the tested conditions | PubMed record states no known competing financial interests; funding was not stated in the accessible abstract | A limited short-term laboratory observation after one intramuscular exposure | A veterinary dose, safety by another route, repeated-use safety, or benefit in a canine patient |
| Xu et al., 2020—repeat-dose component | Healthy male and female Beagles; dog denominator not stated in the accessible abstract or FDA summary | Intramuscular administration for 28 days, followed by 14 days of recovery; vehicle control | The authors’ abstract described the material as generally well tolerated. FDA’s later reanalysis identified prolonged aPTT in dogs and sex-/group-specific laboratory changes involving triglycerides, potassium, glucose, and creatinine. | Same publication; PubMed record states no known competing financial interests | Short-duration toxicology signals that deserve attention | Long-term safety, safety in older or sick dogs, safety with common medications, route-specific safety for oral or subcutaneous products, or clinical benefit |
Limitations of this ledger: The full He et al. paper was available. The full Xu et al. paper was not; the PubMed abstract and FDA’s detailed regulatory summary control that row. The Xu canine denominator was not available in those accessible sources. Negative search findings are limited to the date and search terms used. Healthy laboratory Beagles are not older, injured, medicated, client-owned dogs.
Why this is the most misread part of the topic
What most owners get wrong
“There is a dog study” and “it works in dogs” are not the same sentence. A pharmacokinetic study tells researchers how quickly a tested substance moved through a healthy dog’s blood. It cannot tell you whether that substance repaired a torn ligament. The dog papers are real. They answer a different question than the one you came here with.
There is also a route problem. The dog work used intravenous or intramuscular administration. FDA reported no dog pharmacokinetic or repeat-dose toxicology data for oral, rectal, under-the-skin, or nasal routes in the material it reviewed. Because bioavailability by those routes was unknown, FDA said the intramuscular laboratory safety level could not be used to estimate a safe level for them.
So an oral or under-the-skin dog protocol found online is not supported by canine route-specific efficacy data—and the studies above do not turn it into one.
4. What it might do, and what is actually proven
Rodent and laboratory studies have produced biological signals worth testing. FDA’s review describes findings in rodent gastrointestinal, liver, fistula, and wound-healing models, while other preclinical literature is used to support tendon and ligament claims. None of that has been confirmed in a dog with a clinical condition.
FDA also reported that the molecular targets have not been identified and the mechanism remains poorly understood. In one cited rodent model, different tested exposure levels produced effects of similar magnitude, so a dose-response relationship was not established. That weakens what can be inferred from the result; it does not prove the result is false.
| Claimed use | Controlled canine efficacy trial located | Other evidence located | Publishable conclusion |
|---|---|---|---|
| Torn or partial cranial cruciate ligament (CCL/CrCL) | None | Rodent tendon/ligament and mechanistic work | Benefit not established in dogs |
| Osteoarthritis pain | None | Preclinical mechanisms plus healthy-dog PK/toxicology | Benefit not established in dogs |
| Gastrointestinal disease | None | Predominantly rodent work; limited human material reviewed by FDA | Benefit not established in dogs |
| Wound healing | None | Rodent and laboratory models | Benefit not established in dogs |
| Recovery after surgery | None | Indirect preclinical claims | Benefit not established in dogs |
| BPC-157 combined with TB-500 | None | Marketing and anecdotal claims; no relevant canine controlled trial located | Combination benefit and safety not established |
Combining two unapproved substances does not solve the evidence problem. It adds a second identity and safety question and makes it harder to know which substance produced a benefit or harm.
For context on the human side—because it is often repeated as though it settles the dog question—FDA located five human clinical studies using BPC-157. The only randomized ulcerative-colitis trial was available as a 2005 meeting abstract: 53 people were randomized, 46 completed the study, and the estimated difference between groups had a confidence interval that crossed zero. FDA concluded that the abstract lacked enough detail to support efficacy or safety for that use.
The honest version: we are not saying BPC-157 does nothing. Decades of rodent work are not nothing, and some of it is genuinely interesting. We are saying nobody has shown that it helps a dog with the condition you are worried about, and a rat’s tissue response is not your dog’s cruciate ligament.
5. Safety: what is known, and what nobody knows
BPC-157 should not be described as proven safe for dogs. FDA’s review of the 28-day intramuscular study identified prolonged activated partial thromboplastin time, or aPTT, in dogs and other sex- and group-specific laboratory changes involving triglycerides, potassium, glucose, and creatinine. FDA’s overall rat-and-dog assessment called the repeat-dose findings clinically relevant safety signals.
That is narrower—and more accurate—than saying the dog study showed raised ALT, glucose, and triglycerides. The ALT increase in FDA’s detailed discussion was a rat finding, and the reported dog glucose changes were decreases in certain groups.
Why two credible summaries sound different
The 2020 paper’s abstract says BPC-157 was generally well tolerated under its laboratory conditions. FDA later read the same study for a regulatory decision and focused on unresolved laboratory changes, route gaps, and study limits. Both summaries exist. Neither is a verdict about an individual dog.
Here is what the evidence boundary looks like:
- Clotting behavior changed in dogs. aPTT is a laboratory measure of one part of the clotting process. FDA reported prolongation in male dogs in parts of the study.
- Other dog laboratory values changed. FDA’s detailed review identifies group-specific changes involving triglycerides, potassium, glucose, and creatinine. The clinical meaning for real canine patients is not established.
- The repeat-dose study was short. It lasted 28 days, followed by a 14-day recovery period.
- The tested route was narrow. The dog toxicology work used intramuscular administration, not the oral or under-the-skin routes owners commonly encounter online.
- No carcinogenicity study was identified. FDA said it did not find carcinogenicity studies for BPC-157 free base or acetate. That means the long-term cancer question is unknown—not that cancer is known to occur and not that it has been ruled out.
A seller label or purity number does not establish identity or sterility
This is separate from biology, and for an injected product it may matter more.
In the nomination materials FDA reviewed, the certificates and supporting data did not adequately characterize peptide-related impurities, aggregates, microbial bioburden, or bacterial endotoxins. FDA also found inconsistent naming and different active substances sold under the same common name.
FDA raised immunogenicity as another concern for certain routes: a peptide, its aggregates, or its impurities may trigger an immune response. The current FDA human-compounding safety-risk page still lists BPC-157 and says the agency has limited safety information for proposed routes. Those statements come from a human compounding review; they do not quantify a dog’s risk, but they do expose a product-quality gap that a canine efficacy claim cannot erase.
A purity percentage by itself is not proof of identity, sterility, potency, freedom from endotoxin, or independent verification.
What has actually been reported
FDA’s human adverse-event search retrieved three reports involving injectable BPC-157 through December 4, 2025: an injection-site reaction in a person also using thymosin; shortness of breath followed by an emergency-room visit; and reproducible skin and gum darkening after use of a BPC-157/TB-500 product labeled for research purposes. FDA emphasized that these reports cannot establish causation and that the available details were limited.
Those are human reports, not dog outcomes.
For animals, FDA does accept adverse-event and product-defect reports involving compounded or unapproved drugs through Form FDA 1932a. But no BPC-157-specific canine surveillance summary or published canine case series was located. A missing public count is not evidence of safety.
If you have already given it
Tell your veterinarian what happened, even if you are embarrassed about where the product came from. Bring the container and label. If anything has changed, call rather than waiting for a particular symptom to appear. This page cannot tell you whether to continue or stop a product or what monitoring your dog needs.
6. What it costs
We are not publishing a BPC-157 price, and the reason is the point. No standardized FDA-approved canine product or verifiable veterinary market price was identified. Online seller prices were excluded because they do not establish the active substance, a legitimate veterinary pathway, or the full cost of care.
A price range would imply that comparable products are being measured. FDA’s own review found naming and characterization problems that make that assumption unsafe. This is a stated data boundary under our cost data methodology, not an oversight.
What we can help with is the estimate actually sitting in front of you.
| Cost component | Why it may be needed | Included in an online product price? |
|---|---|---|
| Examination | Establishes the likely cause and how urgent it is | No |
| Imaging or laboratory work | Confirms or rules out the condition and may establish a baseline | No |
| Procedure or established medication | The actual treatment plan | No |
| Anesthesia and monitoring | Required for many orthopedic procedures | No |
| Rechecks | Shows whether the plan is working or needs to change | No |
| Rehabilitation | Often central to recovery and mobility | No |
| Complication care | Cannot be predicted from a product listing | No |
If two veterinary estimates look far apart, they may be measuring different things. Ask for both itemized and compare line by line rather than bottom line to bottom line.
7. Insurance: the honest answer
Do not assume BPC-157 is covered. No current policy-specific BPC-157 coverage determination was verified for this page. Coverage depends on the actual policy form and endorsements, the state, the eligible-expense and treatment definitions, exclusions, prescription and medical-necessity terms, the effective date, waiting periods, reimbursement rules, and the facts of the claim.
If your dog already had related signs, a diagnosis, or treatment advice before coverage began or during a waiting period, a new policy will generally treat related care as pre-existing. Definitions and any curable-condition provisions vary, so the controlling policy still has to be read.
If you already have coverage, ask the insurer in writing about the specific proposed charge and keep the response with the claim file. See our insurance coverage methodology for the provisions that control these answers, and the Pet Insurance Reference if you are planning ahead before any condition exists.
There is no quote link on this page. For readers whose dog already has related signs or a diagnosis, a policy bought today generally would not pay for that existing problem, and offering a quote here would sell that misunderstanding.
8. Access and established alternatives
No approved canine BPC-157 product or verified seller pathway was located. This page does not name suppliers, link to research-chemical sellers, or explain how to obtain a product labeled against veterinary use. That is a standing rule under our editorial standards, not a conversion decision about this page.
The legal and access picture needs one clean distinction:
- Office stock: Under GFI #256, FDA’s enforcement-discretion pathway for animal drugs compounded from bulk substances and kept as office stock is tied to a specific dynamic list or substances currently under review. BPC-157 was on neither list when checked.
- Patient-specific prescriptions: GFI #256 treats these separately. The identified patient, the veterinarian’s medical rationale, whether an approved or indexed drug can appropriately treat that patient—or whether a compounded difference would produce a clinical difference—documentation, the compounder’s practices, and federal and state requirements can all matter. The office-stock list does not by itself answer every individual case.
- Regulatory status: A patient-specific compounded preparation made from a bulk substance remains an unapproved animal drug. Enforcement discretion is not approval, proof of quality, or proof that it works.
So a veterinarian’s answer may turn on evidence, product identity and quality, monitoring, clinic policy, federal guidance, state law, and the facts of the dog’s case. This page cannot pre-decide that answer.
If a veterinarian raises BPC-157, ask for the exact active substance and form, the compounding pharmacy, the medical rationale, the evidence for this dog’s diagnosis, the monitoring plan, the full cost, the alternatives, and what would make the plan stop or change. See how we verify a pharmacy and the site’s Pharmacy & Access section.
The useful decision is not which peptide listing to buy. It is what is wrong and which established path fits it.
| Your dog’s situation | What is established | Read or do next | Boundary |
|---|---|---|---|
| Osteoarthritis pain | FDA-approved options with reviewed canine evidence exist | Librela · Galliprant | Neither is right for every dog; read each record’s safety limits |
| Canine joint disease; injectable option under consideration | Adequan Canine is FDA approved for stated canine joint indications | Adequan Canine—active recall: lots 3369 and 25011; affected lots should not be used | Does not replace diagnosis; verify the lot before use |
| Torn or partial CCL/CrCL | Surgical and non-surgical paths both exist; choice depends on the patient | Dog ACL surgery cost and quote checklist | A website cannot assess knee stability or choose a procedure |
| Limping without a diagnosis | A hands-on examination; imaging or tests when indicated | In-person veterinary visit | A remote service cannot test a joint or rule out serious injury |
| Gastrointestinal signs | Diagnosis first because causes and urgency differ | Veterinary evaluation | There is no general “gut healing” answer |
| Recovery after surgery | The surgeon’s activity, wound, pain-control, and rehabilitation plan | Contact the surgical team | An online peptide protocol should not replace postoperative instructions |
9. The appropriate next step
Start with the diagnosis, then make the treatment decision. If a veterinarian has already named BPC-157, use the questions below to turn a vague peptide conversation into a concrete clinical one.
Take these eight questions to your appointment
Fifteen minutes goes fast. These are written to get a real answer about your dog, not a general opinion about peptides. Nothing to sign up for, nothing collected.
- What exactly is the diagnosis, and what is it based on?
- What are you recommending, and what result would tell us it is working?
- When would we reassess, and what would make us change course?
- What established options belong in this decision, including doing less for now?
- What is the full cost—exam, imaging, procedure, medication, rechecks, and rehabilitation?
- I read about an unapproved product online. What would you want me to know about its identity, evidence, and risks?
- What should I watch for at home that means call you or go to emergency care?
- Is a referral or a second opinion worth it in this case?
Not sure whether this needs an in-person visit? See what an online veterinarian can and cannot do. A remote service cannot examine the joint, test stability, take images, run immediate emergency treatment, or guarantee a prescription. Anything urgent belongs in front of a veterinarian in person.
What we actually verified
Checked on August 29, 2026:
- FDA’s BPC-157 briefing document, memorandum dated May 11, 2026, prepared for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. It is the primary source for FDA’s characterization findings, dog-study reanalysis, route gaps, human clinical-study summary, adverse-event search, and staff recommendation.
- FDA’s July 23–24, 2026 PCAC meeting page, including the use FDA evaluated for BPC-157.
- FDA’s current 503A bulk-substance framework, 21 CFR 216.23, and FDA’s BPC-157 safety-risk entry.
- FDA CVM’s office-stock list, bulk substances currently under review, and GFI #256 Q&A, including the separate treatment of office stock and patient-specific prescriptions.
- The full open-access He et al. 2022 paper, the Xu et al. 2020 PubMed record, and FDA’s detailed summary of the Xu canine work.
- FDA’s Adequan Canine recall notice for lots 3369 and 25011.
- The ASPCA Animal Poison Control Center phone number, 24/7 availability, and fee language.
What remains a dated evidence boundary:
- No controlled canine efficacy trial was located. That is a search finding through August 29, 2026—not proof that no unpublished work exists.
- The full Xu et al. paper was not accessible; FDA’s regulatory summary and the PubMed abstract are the sources for its details. The dog denominator was not available in those accessible materials.
- No legitimate standardized US veterinary price or verified seller pathway was identified.
- No pharmacy’s willingness or ability to fill a particular veterinary prescription was verified.
- State-by-state veterinary and pharmacy rules were not adjudicated.
- No policy-specific pet-insurance coverage decision for BPC-157 was verified.
- No BPC-157-specific public canine adverse-event count or case series was located.
No compensated links appear on this page. No seller, pharmacy, insurer, provider, or product paid for placement, inclusion, or any conclusion. Read our full disclosure.
If a status, source, or figure is wrong or has gone stale, tell us. We re-check the human compounding status every 30 days while it is moving, and the canine literature, animal-compounding pages, and internal destinations every 90 days.
Common questions
Is BPC-157 FDA approved for dogs?
No. Checks of Animal Drugs @ FDA, the Green Book, and the FDA Index on August 29, 2026 found no approved, conditionally approved, or indexed BPC-157 product for dogs. FDA’s May 2026 human-drug review also reported no approved BPC-157 product in any country at the time of its search.
Are there BPC-157 studies in dogs?
Yes—two published papers involving healthy Beagles. One measured pharmacokinetics in six dogs and reported an intravenous half-life of about 5.27 minutes. The other reported acute and 28-day intramuscular toxicology work. Neither tested whether a condition healed.
Is BPC-157 safe for dogs?
Not established. FDA’s reanalysis of the 28-day dog study identified prolonged aPTT and other group-specific laboratory changes. The study was short, used healthy laboratory dogs, and did not establish safety for oral or under-the-skin routes, sick dogs, or long-term use.
Does BPC-157 work for a torn ACL or CCL in dogs?
Not established. No controlled canine efficacy trial was located. FDA also reported that it did not identify human tendonitis clinical studies when that use was nominated for the separate human 503A review.
Why does this page not give a dose?
Because the dog studies did not establish a clinical canine dose, route-specific data are missing for products commonly promoted online, product identity may be unclear, and dosing requires diagnosis and clinical judgment. Laboratory exposure levels are not owner instructions.
Did FDA approve BPC-157 in July 2026?
No. The July meeting concerned possible inclusion on a human pharmacy-compounding list, not animal-drug approval. Advisory recommendations are nonbinding, FDA staff recommended against listing, and BPC-157 was not in 21 CFR 216.23 when checked.
Can my veterinarian prescribe or have it compounded?
The answer is fact-specific. BPC-157 is not on FDA’s animal office-stock list, but GFI #256 treats patient-specific prescriptions separately. Any proposal still involves an unapproved compounded animal drug and depends on the veterinarian’s rationale, the identified patient, the compounder, federal guidance, state requirements, and the available alternatives.
Does pet insurance cover BPC-157?
Do not assume it does. No policy-specific BPC-157 determination was verified. The policy form, state, eligible-expense definitions, exclusions, medical-necessity and prescription terms, effective date, waiting period, and pre-existing-condition facts control the claim.
The Pet Treatment Index is an independent publication. It is not a veterinary practice, pharmacy, insurer, insurance producer, manufacturer, clinic, or government agency, and it is not affiliated with FDA. This page is educational information only—not veterinary advice, a diagnosis, or a treatment recommendation. If you believe your pet may be experiencing an emergency, contact a veterinarian or emergency animal hospital immediately. See our veterinary disclaimer, editorial standards, and evidence methodology.
Record status: Regulatory status—No established veterinary marketing status located. Evidence stage—4: Preclinical or other-species evidence. Both labels are defined in our evidence methodology and apply only to the species, claims, routes, and verification date stated on this page.